The market for treatments for Huntington’s disease was anticipated to be worth US$ 360 million in 2021 and is projected to increase at a CAGR of 20% between 2022 and 2032. By the end of 2032, the market is anticipated to reach US$ 2.7 billion.
The global COVID-19 epidemic caused a modest growth rate of 7% in the market from 2019 to the middle of 2020. Online pharmacies were offering off-label medications such antipsychotics, antidepressants, and anticonvulsants to treat HD symptoms during the COVID-19 epidemic. The government-imposed blackout caused the COVID-19 pandemic clinical studies to be delayed.
What are the specific drivers of the Huntington’s disease Treatment Market?
Growing Use of Better Medical Therapies and Treatments to Increase Demand for Effective Therapies
- The engagement of leading industry participants in the search for a solution for Huntington’s disease is anticipated to fuel market expansion (HD). Disease prevalence and the patient population are both rising globally, primarily in North America and Europe. The absence of disease-modifying medications and other forms of treatment for HD patients will provide a further beneficial contribution to the market’s expansion.
- Stem cell therapy is attracting investigation as a potential HD treatment. The CELLAVITA-HD stem cell therapy, which Cellavita and AzidusPharma are developing together, is used in the ADORE-DH phase 2/ phase 3 experiment. Also, alternative therapeutic choices like speech therapy, psychiatric care, and physiotherapy had a favourable effect on the market expansion for the treatment of Huntington’s disease.
Increasing R&D efforts to spur market expansion
- The absence of an effective cure or therapy for Huntington’s disease continues to facilitate research and development of new therapeutic strategies. During the course of the forecast period, this is anticipated to significantly enhance market growth. Government programmes that support the creation of new pharmaceuticals are another significant factor in the market’s expansion.
- Due to rising illness prevalence and increased R&D activity by institutions and universities over the forecast period, the global market for treatments for Huntington’s disease is anticipated to expand. According to the Huntington’s disease Society of America, there are roughly 30,000 Individuals with symptoms and more than 200,000 people who are at risk of inheriting the illness.
How will the growth emerge in the North American region during the forecast period?
The North American market is anticipated to generate 77% of the total global revenue for therapies for Huntington’s disease in 2022. The high frequency of Huntington’s disease, the rising cost of healthcare, technological advancements, and proactive government activities have all contributed to an increase in awareness of and sales of medications used to treat the condition.
To help the market grow, some of the top manufacturers, including H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., have launched symptom management medicines.
What can be expected from the Symptomatic Treatment Segment during the forecast period?
The market for treating Huntington’s disease is anticipated to rule during the forecast period, with symptomatic treatment predicted to generate 98% of market revenue in 2022. This market’s expansion is due in part to a number of symptom management products and their patent protection. Xenazine and austedo are the first-line treatments for Huntington’s chorea. Research and development of possible Huntington’s disease product candidates may help this market flourish.
The US Food and Drug Administration recognised SOM3355, a medication from SOM BIOTECH for the treatment of chorea linked to Huntington’s disease, as an orphan medicine in October 2021.
This is for the purpose of treating the chorea brought on by Huntington’s disease. As a result, following FDA approval, the product will only be offered in the United States.